Novo Nordisk announced on Monday that an advanced-phase clinical trial showed 40.4% of children aged 6 to under 12 treated with semaglutide no longer classified as obese after 68 weeks, provided the treatment was fully complied with. ^[3] The results come as global hunger figures remain high, with approximately 19.5 million people facing acute hunger at the end of 2025 and around 825,000 children under five years old expected to suffer severe malnutrition in 2026. ^[1] In Senegal, The Global Nutrition Report indicates that one in ten children under five suffers from acute malnutrition, only 10% of infants aged 6-23 months receive an acceptable diet, and 52% of reproductive-aged women suffer from anemia. ^[2] The Novo Nordisk announcement noted that the 40.4% outcome occurred only when treatment compliance was fully maintained. ^[3] The read here is that the trial data highlights the dependency of clinical outcomes on strict adherence to the medication regimen. ^[3]